Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area.

NCT04529564 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04529564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04529564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 12, 2020
Completion date
June 29, 2023
Enrollment
106 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung